Antagonistic effects of naloxone and naloxonazine on sufentanil-induced antinociception and respiratory depression in rats

Pain

Volumn 83, Issue 1, 1999, Pages 17-24

  Verborgh, Christian ^a   Meert, Theo F ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Naloxonazine; Naloxone; Respiratory depression; Spinal analgesia; Sufentanil

Indexed keywords

MU OPIATE RECEPTOR; NALOXONAZINE; NALOXONE; RECEPTOR SUBTYPE; SUFENTANIL;

ANIMAL MODEL; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATION DEPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS, OPIOID; ANESTHESIA, SPINAL; ANIMALS; ANOXIA; HYPERCAPNIA; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; MALE; NALOXONE; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, OPIOID, MU; RESPIRATION; SUFENTANIL;

EID: 0032870040     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(99)00068-8     Document Type: Article

References (33)

1. Albeck H., Woodfield S., Kreek M.J. Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. J Chromatogr. 488:1989;435-445.
2. Colpaert F.C., Leysen J.E., Michiels M., van den Hoogen R.H. Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 65:1986;41-49.
3. Garrett E.R., Shyu W.C., Ulubelen A. Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. J Pharm Sci. 75:1986;1127-1136.
4. Garzon J., Sanchez-Blazquez P. In vivo injection of antibodies directed against the cloned mu opioid receptor blocked supraspinal analgesia induced by mu-agonists in mice. Life Sci. 56:1995;PL237-PL242.
5. Gatch M.B., Negus S.S., Mello N.K., Liguori T., Bergman J. Naloxonazine antagonism of levorphanol-induced antinociception and respiratory depression in Rhesus monkeys. Eur J Pharmacol. 298:1996;31-36.
6. Hahn E.F., Carroll-Buatti M., Pasternak G.W. Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. J Neurosci. 2:1982;572-576.
7. Hahn E.F., Pasternak G.W. Naloxonazine, a potent, long-lasting inhibitor of opiate binding sites. Life Sci. 31:1982;1385-1388.
8. Heyman J.S., Williams C.L., Burks T.F., Mosberg H.I., Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J Pharmacol Exp Ther. 245:1988;238-243.
9. Kamei J., Ohsawa M., Saitoh A., Iwamoto Y., Suzuki T., Misawa M., Nagase H., Kasuya Y. Modification of μ-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes. J Pharmacol Exp Ther. 274:1995;700-706.
10. Kamei J., Saitoh A., Suzuki T., Misawa M., Nagase H., Kasuya Y. Buprenorphine exerts its antinociceptive activity via μ-1 opioid receptors. Life Sci. 56:1995;PL285-PL290.
11. Ling G.S., Spiegel K., Nishimura S.L., Pasternak G.W. Dissociation of morphine's analgesic and respiratory depressant actions. Eur J Pharmacol. 86:1983;487-488.
12. Ling G.S., Spiegel K., Lockhart S.H., Pasternak G.W. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther. 232:1985;149-155.
13. Ling G.S., Simantov R., Clark J.A., Pasternak G.W. Naloxonazine actions in vivo. Eur J Pharmacol. 129:1986;33-38.
14. Lutz R.A., Cruciani R.A., Munson P.J., Rodbard D. Mu1: a very high affinity subtype of enkephalin binding sites in rat brain. Life Sci. 36:1985;2233-2238.
15. Meert T.F., Mesens J., Peeters J., Putteman P. 2-Hydroxypropyl-β-cyclodextrin can modulate the activity of epidurally and intrathecally administered opioids. Hedges A.R. Minutes of the Sixth International Symposium on Cyclodextrins. 1992;431 Editions de Sante.
16. Meert T.F., De Kock M. Interactions between the lipophilic opioid sufentanil and clonidine in rats after spinal application. Acta Anaesth Scand. 39:1995;527-534.
17. Meert T.F. Pharmacotherapy of opioids: present and future developments. Pharm World Sci. 18:1996;1-15.
18. Moskowitz A.S., Goodman R.R. Autoradiographic analysis of mu1, mu2, and delta opioid binding in the central nervous system of C57BL/6BY and CXBK (opioid receptor-deficient) mice. Brain Res. 360:1985;108-116.
19. Moskowitz A.S., Goodman R.R. Autoradiographic distribution of mu1 and mu2 opioid binding in the mouse central nervous system. Brain Res. 360:1985;117-129.
20. Negus S.S., Pasternak G.W., Koob G.F., Weinger M.B. Antagonist effects of beta-funaltrexamine and naloxonazine on alfentanil-induced antinociception and muscle rigidity in the rat. J Pharmacol Exp Ther. 264:1993;739-745.
21. Ngai S.H., Berkowitz B.A., Yang J.C., Hempstead J., Spector S. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology. 44:1976;398-401.
22. Paakkari P., Paakkari I., Siren A.L., Feuerstein G. Respiratory and locomotor stimulation by low doses of dermorphin, a mu1 receptor-mediated effect. J Pharmacol Exp Ther. 252:1990;235-240.
23. Pasternak G.W., Childers S.R., Snyder S.H. Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. Science. 208:1980;514-516.
24. Pasternak G.W., Childers S.R., Snyder S.H. Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro. J Pharmacol Exp Ther. 214:1980;455-462.
25. Pasternak G.W., Wood P.J. Multiple mu opiate receptors. Life Sci. 38:1986;1889-1898.
26. Paul D., Bodnar R.J., Gistrak M.A., Pasternak G.W. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur J Pharmacol. 168:1989;307-314.
27. Pick C.G., Paul D., Pasternak G.W. Comparison of naloxonazine and β-funaltrexamine antagonism of μ-1 and μ-2 opioid actions. Life Sci. 48:1991;2005-2011.
28. Pick C.G., Nejat R.J., Pasternak G.W. Independent expression of two pharmacologically distinct supraspinal mu analgesic systems in genetically different mouse strains. J Pharmacol Exp Ther. 265:1993;166-171.
29. Simone D.A., Bodnar R.J., Portzline T., Pasternak G.W. Antagonism of morphine analgesia by intracerebroventricular naloxonazine. Pharmacol Biochem Behav. 24:1986;1721-1727.
30. Verborgh C., Camu F., Meert T.F. Interaction between sufentanil and U-50488H in terms of antinociception and respiratory depression in rats. Acta Anaesthesiol Scand. 41:1997;895-902.
31. Wolozin B.L., Pasternak G.W. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci USA. 78:1981;6181-6185.
32. Xu S.F., Lu W.X., Zhou K.R., He X.P., Niu S.F., Xu W.M., Zhang A.Z., Weber E., Chang J.K. The analgesic and respiratory depressant actions of metorphamide in mice and rabbits. Neuropeptides. 6:1985;121-131.
33. Zhang A.Z., Pasternak G.W. Ontogeny of opioid pharmacology and receptors: high and low affinity site differences. Eur J Pharmacol. 73:1981;29-40.